U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19N3O2
Molecular Weight 309.3624
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CGS-20625

SMILES

COC1=CC=C(C=C1)N2N=C3C(=CNC4=C3CCCCC4)C2=O

InChI

InChIKey=XRUUVUYJUULCBQ-UHFFFAOYSA-N
InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,19H,2-6H2,1H3

HIDE SMILES / InChI
Molecular Formula C18H19N3O2
Molecular Weight 309.3624
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8576841

CGS-20625 is a potent and selective ligand for the central benzodiazepine receptor. It acts as a partial agonist of GABAA channel in vitro and produces anxiolytic and anticonvulsant effects in vivo. The drug has low bioavailability so its clinical applications are limited, and it is mainly used as a tool compound.

CNS Activity

CNS Active
3913
Curator's Comment: CNS active in rats.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Partial Agonist
290
 1.3 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
CGS 20625, a novel pyrazolopyridine anxiolytic.
1989 Jan
Patents

Patents

US 4647566 A
1

Sample Use Guides

In Vivo Use Guide
In clinical studies of CGS-20625 pharmacokinetics, the drug was administered orally as a powder (20 mg), as PEG 400 solution or in gelatin capsules.
Route of Administration: Oral
In Vitro Use Guide
The affinity of CGS-20625 with respect to central benzodiazepine receptor was measured using 0.2 nM [3H]FNZ as a radioligand. Receptors from rat forebrain were incubated with Tris-cation buffer at 23°C for 45 min. Non-specific activity was measured using 1mM GABA.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:47:33 GMT 2023
Edited
by admin
on Fri Dec 15 15:47:33 GMT 2023
Record UNII
K9Q4R9S81O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CGS-20625
Common Name English
CYCLOHEPTA(B)PYRAZOLO(3,4-D)PYRIDIN-3(2H)-ONE, 5,6,7,8,9,10-HEXAHYDRO-2-(4-METHOXYPHENYL)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID30912046
Created by admin on Fri Dec 15 15:47:33 GMT 2023 , Edited by admin on Fri Dec 15 15:47:33 GMT 2023
PRIMARY
CAS
111205-55-1
Created by admin on Fri Dec 15 15:47:33 GMT 2023 , Edited by admin on Fri Dec 15 15:47:33 GMT 2023
PRIMARY
FDA UNII
K9Q4R9S81O
Created by admin on Fri Dec 15 15:47:33 GMT 2023 , Edited by admin on Fri Dec 15 15:47:33 GMT 2023
PRIMARY
WIKIPEDIA
CGS-20625
Created by admin on Fri Dec 15 15:47:33 GMT 2023 , Edited by admin on Fri Dec 15 15:47:33 GMT 2023
PRIMARY
Related Record Type Details
Structure of CGS-20625
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966